tbuckley/cabot-search huggingface dataset:
Endometrial cancer survivors: What is their knowledge about obesity?
Authors: Leslie Horn Clark, Emily Meichun Ko, Amber Kernodle, Ariel Harris, Dominic T. Moore, Paola A. Gehrig, Victoria Lin Bae-Jump
Journal: Journal of Clinical Oncology (2014)

5599 Background: Obesity is a well-established risk factor for development of endometrial cancer (EC); it has been linked to decreased survival, worse surgical outcomes, and poor quality of life in EC patients. We sought to assess EC survivor’s awareness of obesity and its role in EC. Methods: Following IRB approval, women diagnosed with EC from 2011 – 2012 were identified. Patients with persistent/recurrent disease or those actively undergoing treatment were excluded. A pre-survey invitation to participate was sent 1 week prior to the survey. Surveys were mailed to 233 women. Reminder postcards were sent 2 weeks following the survey. Demographics, weight and weight assessment, patient’s health behaviors, and information regarding physician counseling was collected. Along with descriptive statistics, the kappa statistic was reported as a measure of agreement. Results: Of 233 surveys sent, 46% (n=108) were returned. The median BMI of responders was 29.8 (range 17.1-64.8) When asked to identify their BMI into four categories, 14% self-reported as “normal weight”, 3% as “underweight”, 39% as “a little overweight”, and 44% as “a lot overweight”. Self-reported BMI assessment was compared to actual BMI and good to moderate agreement was noted (weighted kappa 0.66). 85% of women correctly identified their BMI category. When asked if they were obese, 96% (43/45) of obese patients correctly answered “yes” (kappa 0.86). 52% (n=46) reported attempted weight loss following their diagnosis. Of those not attempting weight loss, reasons included: not needing to (37%), not wanting to (23%), not knowing how (14%), not having time (12%), and not having money (20%). Only 34% of patients reported being counseled by a gynecologic oncologist to lose weight. 92% of patients correctly identified obesity as a risk factor for EC. Conclusions: EC survivors are relatively knowledgeable about the role of obesity in EC and their own personal weight. Patients were generally motivated to make lifestyle changes after their cancer diagnosis. Unfortunately, only 1/3 of patients reported their providers encouraged weight loss. Gynecologic oncologists should take full advantage of the “teachable moment” for this highly obesity-driven cancer.
Changing use and attitudes towards teledermatology in the U.K. over 10 years: results of the 2016 National Survey
Authors: S.H. Mehrtens, S.M. Halpern
Journal: British Journal of Dermatology (2017)

Dermatology has been described as a speciality in crisis in the UK, with a shortfall of 250 dermatologists nationally combined with steadily increasing referrals and skin cancer incidence1. This has fuelled interest in teledermatology (TD). TD utilises telecommunication technology at a distance to exchange medical information. Most commonly this is via store and forward techniques, which involve transmission of patient images and information to a teledermatologist to enable consultation not in real-time.

This article is protected by copyright. All rights reserved.
Suggestions for Increasing Diversity in Clinical Trials
Authors: Ajay Kailas, Morgan Dawkins, Susan C. Taylor
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis
Authors: Vicente Planells-Palop, Ali Hazazi, Julia Feichtinger, Jana Jezkova, Gerhard Thallinger, Naif O. Alsiwiehri, Mikhlid Almutairi, Lee Parry, Jane A. Wakeman, Ramsay J. McFarlane
Journal: Molecular Cancer (2017)

Cancer/testis (CT) genes have expression normally restricted to the testis, but become activated during oncogenesis, so they have excellent potential as cancer-specific biomarkers. Evidence is starting to emerge to indicate that they also provide function(s) in the oncogenic programme. Human TEX19 is a recently identified CT gene, but a functional role for TEX19 in cancer has not yet been defined.siRNA was used to deplete TEX19 levels in various cancer cell lines. This was extended using shRNA to deplete TEX19 in vivo. Western blotting, fluorescence activated cell sorting and immunofluorescence were used to study the effect of TEX19 depletion in cancer cells and to localize TEX19 in normal testis and cancer cells/tissues. RT-qPCR and RNA sequencing were employed to determine the changes to the transcriptome of cancer cells depleted for TEX19 and Kaplan-Meier plots were generated to explore the relationship between TEX19 expression and prognosis for a range of cancer types.Depletion of TEX19 levels in a range of cancer cell lines in vitro and in vivo restricts cellular proliferation/self-renewal/reduces tumour volume, indicating TEX19 is required for cancer cell proliferative/self-renewal potential. Analysis of cells depleted for TEX19 indicates they enter a quiescent-like state and have subtle defects in S-phase progression. TEX19 is present in both the nucleus and cytoplasm in both cancerous cells and normal testis. In cancer cells, localization switches in a context-dependent fashion. Transcriptome analysis of TEX19 depleted cells reveals altered transcript levels of a number of cancer-/proliferation-associated genes, suggesting that TEX19 could control oncogenic proliferation via a transcript/transcription regulation pathway. Finally, overall survival analysis of high verses low TEX19 expressing tumours indicates that TEX19 expression is linked to prognostic outcomes in different tumour types.TEX19 is required to drive cell proliferation in a range of cancer cell types, possibly mediated via an oncogenic transcript regulation mechanism. TEX19 expression is linked to a poor prognosis for some cancers and collectively these findings indicate that not only can TEX19 expression serve as a novel cancer biomarker, but may also offer a cancer-specific therapeutic target with broad spectrum potential.
SPORTS SPECIALIZED RISKS FOR REINJURY IN YOUNG ATHLETES: A 2+ YEAR CLINICAL PROSPECTIVE EVALUATION
Authors: Neeru Jayanthi
Journal: British Journal of Sports Medicine (2017)

Background We previously demonstrated an independent risk of sports specialization in young athletes. However, there is no longitudinal study on the risks of sports specialization and reinjury in young athletes. Objective To determine the longitudinal risk factors for sports specialization in a clinical population of young athletes. To outline the patterns of reinjury in this clinical population. Design Prospective cohort observational study. Setting Multicenter clinical study from sports medicine clinics and pediatric/family medicine offices. Patients (or Participants) Young athletes 7–18 years old presenting for sports-related injury to a sports medicine clinic or for for a sports physical. Interventions (or Assessment of Risk Factors) Each subject is enrolled at baseline and then given follow up survey every 6 months for up to 3 years. We assessed the following risk factors: Sex, Age, Age of specialization, degree of sports specialization, training volume (organized, free play), year round training (&gt;8 months). Main Outcome Measurements Injury, injury type (acute, overuse, serious overuse), clinical diagnosis. Results There were 1191 subjects analysed at baseline, with a total of 1083 follow up evaluations for up to 3 years of follow up. There were 39.4% (427/1083) injured follow up evaluations, 60.6%(656/1083) uninjured. Of the 427 injuries, 69.6% (297/427) were a reinjury (142 repeat injury (same location) and 155 recurrent injury. There were 134 new injuries. Injured follow up subjects were more likely to be female (p&lt;0.02), report age of specialization &lt;12 (p=0.03) and participate in year round training&gt;8 mths/yr (p&lt;0.03), and a higher proportion were more highly specialized. Conclusions Young athletes are more likely to develop a reinjury than a new injury on follow ups up to 3 years. Athletes specializing &lt;12 years old and female young athletes were more likely to develop injury. Similar to baseline, there was a higher proportion of injured highly specialized athletes.
OS04.4 Supratotal resection in newly diagnosed glioblastoma: role of this surgical strategy beyond contrast enhancing boundaries
Authors: F. Pessina, P. Navarria
Journal: Neuro-Oncology (2017)

Introduction: The outcome of newly diagnosed glioblastoma multiforme (GBM) patients is poor, with a median survival time of 15–18 months. The extent of surgical resection (EOR) has been diffusely recorded as conditioning survival in glioma; it would be worthwhile to investigate whether to tend toward a maximal resection of the T2/FLAIR signal abnormalities could impact on survival The aim of this study was to evaluate the impact of extent of supratotal resection in newly diagnosed GBMs on PFS and OS. Matherial and Methods: EOR was stratified into five subgroups: (i) supratotal resection (SUPr), in case of surgical resection of 100% of enhanced and Flair alterated areas; (ii) complete resection (CR), corresponding to resection of 100% of enhanced areas with variable RTV of Flair abnormalities; (iii) gross total resection (GTR), between 90 and 99 %; (iv) sub-total resection (STR), between 10 and 89 %; (v) biopsy (B) < 10 %. In addition, in case of CR we dichotomized Flair residual volume in increments of 1 cm3 to eventually evaluate the thresholds for RTV. Results: From December 2003 to November 2015, 282 patients referred to our institution for newly diagnosis GBM were included in this analysis; 105 (37.2%) were female and 177 (62.8%) male with a median age of 61 years (range 21–82 years). All patients underwent surgery followed by concomitant and adjuvant chemo-radiotherapy.SUPr was obtained in 21 patients (7.4%), CR in 22 patients (7.8%), GTR in 38 (13.5%), STR in 143 (50.7%) and biopsy in 58 (20.6%). Regarding PFS the median, 1, 2 and 3 years PFS were 24.5 months, 76%, 52% and 14% for patients undergoing SUPr vs 13.2 months, 59%, 25% and 17 % for patients undergoing CR; in univariate and multivariate analysis EOR, KPS and tumor side (p<0.001) significantly influenced PFS. Regarding OS the median, 1, 2 and 3 years OS were 28.6 months, 90%, 71% and 40% for patients undergoing SUPr vs 17.9 months, 90%, 38% and 23 % for patients undergoing CR; in ­univariate and multivariate analysis EOR (p<0.001), KPS (p<0.001) and tumor side (p<0.02) significantly influenced OS. In all cases of complete enhancing resection, a Flair RTV > 0 cc adversely affected PFS and OS. Conclusions: supratotal resection with complete excision of enhancing and Flair tumor components could represent a safe and feasible treatment for newly diagnosed GBMs, strongly influencing survival.
Randomized comparison of frontline alternating chemotherapy versus brief induction followed by autologous stem cell transplant for aggressive lymphomas
Authors: Maria Alma Rodriguez, Koen Van Besien, Fredrick B. Hagemeister, Sergio Giralt, Peter Mclaughlin, James L. Gajewski, Jorge Romaguera, Issa F. Khouri, Anas Younes, Fernando C. Cabanillas, Richard Champlin
Journal: Blood (2003)
Periendoscopic management of direct oral anticoagulants: a prospective cohort study
Authors: Franco Radaelli, Lorenzo Fuccio, Silvia Paggi, Cesare Hassan, Alessandro Repici, Emanuele Rondonotti, Rossella Semeraro, Milena Di Leo, Andrea Anderloni, Arnaldo Amato, Cristina Trovato, Ivana Bravi, Andrea Buda, Mario de Bellis, Valentina D’Angelo, Sergio Segato, Ottaviano Tarantino, Alessandro Musso, Renato Fasoli, Leonardo Frazzoni, Elisa Liverani, Carlo Fabbri, Emilio Di Giulio, Gianluca Esposito, Flavia Pigò, Andrea Iannone, Francesco Dentali
Journal: Gut (2018)

Objective To assess the frequency of adverse events associated with periendoscopic management of direct oral anticoagulants (DOACs) in patients undergoing elective GI endoscopy and the efficacy and safety of the British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) recommendations (NCT 02734316). Design Consecutive patients on DOACs scheduled for elective GI endoscopy were prospectively included. The timing of DOAC interruption and resumption before and after the procedures were recorded, along with clinical and procedural data. Procedures were stratified into low-risk and high-risk for GI-related bleeding, and patients into low-risk and high-risk for thromboembolic events. Patients were followed-up for 30 days for major and clinically relevant non-major bleeding events (CRNMB), arterial and venous thromboembolism and death. Results Of 529 patients, 38% and 62% underwent high-risk and low-risk procedures, respectively. There were 45 (8.5%; 95% CI 6.3% to 11.2%) major or CRNMB events and 2 (0.4%; 95% CI 0% to 1.4%) thromboembolic events (transient ischaemic attacks). Overall, the incidence of bleeding events was 1.8% (95% CI 0.7% to 4%) and 19.3% (95% CI 14.1% to 25.4%) in low-risk and high-risk procedures, respectively. For high-risk procedures, the incidence of intraprocedural bleeding was similar in patients who interrupted anticoagulation according to BSG/ESGE guidelines or earlier (10.3%vs10.8%, p=0.99), with a trend for a lower risk as compared with those who stopped anticoagulation later (10.3%vs25%, p=0.07). The incidence of delayed bleeding appeared similar in patients who resumed anticoagulation according to BSG/ESGE guidelines or later (6.6%vs7.7%, p=0.76), but it tended to increase when DOAC was resumed earlier (14.4%vs6.6%, p=0.27). The risk of delayed major bleeding was significantly higher in patients receiving heparin bridging than in non-bridged ones (26.6%vs5.9%, p=0.017). Conclusion High-risk procedures in patients on DOACs are associated with a substantial risk of bleeding, further increased by heparin bridging. Adoption of the BSG/ESGE guidelines in periendoscopic management of DOACs seems to result in a favourable benefit/risk ratio. Trial registration number NCT 02734316 ; Pre-results.
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
Authors: P Hari, M-V Mateos, R Abonour, S Knop, W Bensinger, H Ludwig, K Song, R Hajek, P Moreau, D S Siegel, S Feng, M Obreja, S K Aggarwal, K Iskander, H Goldschmidt
Journal: Leukemia (2017)

Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibitor carfilzomib is approved for relapsed or refractory MM (RRMM). In phase 3 trials, carfilzomib-based regimens (ASPIRE, carfilzomib–lenalidomide–dexamethasone; ENDEAVOR, carfilzomib–dexamethasone) demonstrated superior progression-free survival (PFS) compared with standard therapies for RRMM (ASPIRE: lenalidomide–dexamethasone; ENDEAVOR, bortezomib–dexamethasone). This subgroup analysis of ASPIRE and ENDEAVOR evaluated outcomes according to prior ASCT status. In total, 446 patients in ASPIRE and 538 in ENDEAVOR had prior ASCT. Median PFS was longer for carfilzomib-based regimens vs non-carfilzomib-based regimens for patients with prior ASCT (ASPIRE: 26.3 vs 17.8 months (hazard ratio (HR)=0.68); ENDEAVOR: not estimable vs 10.2 months (HR=0.61)), those with one prior line of therapy that included ASCT (ASPIRE: 29.7 vs 17.8 months (HR=0.70); ENDEAVOR: not estimable vs 11.2 months (HR=0.46)), and those without prior ASCT (ASPIRE: 26.4 vs 16.6 months (HR=0.76); ENDEAVOR: 17.7 vs 8.5 months (HR=0.43)). Overall response rates also favored the carfilzomib-based regimens. No new safety signals were detected. This analysis suggests that carfilzomib-based treatment may lead to improvement in PFS and response rates regardless of prior transplant status. Further evaluation is warranted.
Prospective Study of Adenosine on Atrioventricular Nodal Conduction in Pediatric and Young Adult Patients After Heart Transplantation
Authors: Jonathan N. Flyer, Warren A. Zuckerman, Marc E. Richmond, Brett R. Anderson, Tamar G. Mendelsberg, Jennie M. McAllister, Leonardo Liberman, Linda J. Addonizio, Eric S. Silver
Journal: Circulation (2017)

Supraventricular tachycardia is common after heart transplantation. Adenosine, the standard therapy for treating supraventricular tachycardia in children and adults without transplantation, is relatively contraindicated after transplantation because of a presumed risk of prolonged atrioventricular block in denervated hearts. This study tested whether adenosine caused prolonged asystole after transplantation and if it was effective in blocking atrioventricular nodal conduction in these patients.This was a single-center prospective clinical study including healthy heart transplant recipients 6 months to 25 years of age presenting for routine cardiac catheterization during 2015 to 2016. After catheterization, a transvenous pacing catheter was placed and adenosine was given following a dose-escalation protocol until atrioventricular block was achieved. The incidence of clinically significant asystole (≥12 seconds after adenosine) was quantified. The effects of patient characteristics on adenosine dose required to produce atrioventricular block and duration of effect were also measured.Eighty patients completed adenosine testing. No patient (0%; 95% confidence interval, 0-3) required rescue ventricular pacing. Atrioventricular block was observed in 77 patients (96%; 95% confidence interval, 89-99). The median longest atrioventricular block was 1.9 seconds (interquartile range, 1.4-3.2 seconds), with a mean duration of adenosine effect of 4.3±2.0 seconds. No patient characteristic significantly predicted the adenosine dose to produce atrioventricular block or duration of effect. Results were similar across patient weight categories.Adenosine induces atrioventricular block in healthy pediatric and young adult heart transplant recipients with minimal risk when low initial doses are used (25 μg/kg; 1.5 mg if ≥60 kg) and therapy is gradually escalated.URL: http://www.clinicaltrials.gov. Unique identifier: NCT02462941.
P06.02 A multivalent protein for immune checkpoint inhibition at the tumor site
Authors: W. Debinski, A. Rodriguez
Journal: Neuro-Oncology (2017)

Monoclonal antibodies targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4, CTLA-4 on T cells have demonstrated efficacy in a variety of peripheral solid tumors. It is more challenging to exploit the potential of such a therapy in glioblastoma (GBM) patients because of the, e.g., tumor location and expression/distribution of the ligands for PD-1 and CTLA-4. Also, these therapies are not targeted to GBM tumors and hypothetically, the T cells should be inhibited in a tumor environment rather than in the periphery. A potential way to make immune checkpoint inhibitors more specific to GBM tumors is by redirecting them to GBM tumor cells. IL-13.E13K is a mutant of interleukin 13, preserving the binding to interleukin-13 receptor alpha 2 (IL-13R2A), which is highly over-expressed on GBM cells, but not in normal brain tissue. Here we describe the construction of two novel fusion antibodies using IL-13.E3K. The first consists of a single chain Fv (scFv) region of anti-CTLA-4 antibody, combined with an Fc region of human IgG1 and with IL-13.E13K (termed αCTLA4-Fc-IL-13.E13K). The second consists of the same components but with anti-PD-1 scFv instead of the αCTLA-4 (termed αPD1-Fc-IL13.E13K). Both fusion protein immune checkpoint inhibitors demonstrated competition for IL-13R2A as they were able to neutralize cell killing of an IL-13.E13K based cytotoxin. In addition, the redirected immune checkpoint inhibitor αCTLA4-Fc-IL-13.E13K demonstrated similar binding to CTLA-4 as did αCTLA4 antibody (Kd = 3.02E-09M and 3.78E-09M). The αPD1-Fc-IL-13.E13K, also demonstrated similar binding affinity to PD-1 as did αPD1 antibodies (Kd = 4.92E-09M and 4.80E-09M). Thus, αCTLA4-Fc-IL-13.E13K and αPD1-Fc-IL-13.E13K redirected to tumor immune checkpoint inhibitors have a strong affinity for the IL-13R2A while continuing to demonstrate strong affinities for CTLA-4 and PD-1. These and similar constructs have the potential to be more specific in targeting the interaction between GBM cells and immune cells directly in a tumor microenvironment.
High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia
Authors: Aishwarya Ravindran, Janani Sankaran, Eapen K. Jacob, Justin D. Kreuter, C. Christopher Hook, Morie A. Gertz, Timothy G. Call, Rajiv K. Pruthi, Mark R. Litzow, Alexandra P. Wolanskyj, William J. Hogan, Aneel A. Ashrani, Kebede H. Begna, Ariela L. Marshall, Robert A. Kyle, Neil E. Kay, Ronald S. Go
Journal: American Journal of Hematology (2017)